Cellmune 1 mg/g ointment
Tacrolimus
Read all of this leaflet carefully before you start using this medicine because it contains important information for you
Contents of the pack
The active substance in Cellmune, tacrolimus monohydrate, is an immunomodulating agent.
Cellmune is used to treat moderate to severe atopic dermatitis (eczema) in adults who do not respond adequately to or are intolerant of conventional treatments, such as topical corticosteroids.
Once the moderate to severe atopic dermatitis has disappeared or almost disappeared after up to 6 weeks of treatment for a flare, and if you have frequent flares (i.e., 4 or more per year), you can prevent flares from coming back or prolong the time without flares by using Cellmune twice a week.
In atopic dermatitis, the skin's excessive immune reaction causes skin inflammation (itching, redness, dryness). Cellmune modifies the abnormal immune response and relieves skin inflammation and itching.
Warnings and precautions
Consult your doctor if:
Children
Using Cellmune with other medicines and cosmetics
Tell your doctor or pharmacist if you are taking or using or have recently taken or used any other medicines, including those obtained without a prescription.
You can use moisturizing creams and lotions during treatment with Cellmune, but you should not use them during the 2 hours before and 2 hours after applying Cellmune.
The use of Cellmune at the same time as other topical preparations or while taking oral corticosteroids (e.g., cortisone) or oral immunosuppressive medications has not been studied.
Using Cellmune with alcohol
While using Cellmune, alcohol consumption may cause redness or flushing of the skin or face and a feeling of warmth.
Pregnancy and breastfeeding
Do not use Cellmune if you are pregnant or breastfeeding.
Consult your doctor or pharmacist before using any medicine.
Follow your doctor's instructions for using Cellmune exactly. If you are unsure, consult your doctor or pharmacist.
Adults (16 years of age and older)
For adult patients (16 years of age and older), two doses of tacrolimus ointment are available (tacrolimus 0.3 mg/g ointment and tacrolimus 1 mg/g ointment). Your doctor will decide which dose is most suitable for you.
Typically, treatment is started with Cellmune 1 mg/g ointment twice a day, once in the morning and once in the evening, until the eczema disappears. Depending on the response of your eczema, your doctor will decide if the application frequency can be reduced or if the lower dose, tacrolimus 0.3 mg/g ointment, can be used.
Treat each affected area of your skin until the eczema has disappeared. Improvement is usually seen within a week. If you do not see any improvement after two weeks, consult your doctor about other possible treatments.
Your doctor may tell you to use Cellmune 1 mg/g ointment twice a week once your atopic dermatitis has disappeared or almost disappeared. Cellmune 1 mg/g ointment should be applied once a day, twice a week (e.g., Monday and Thursday) to the areas of your body that are usually affected by atopic dermatitis. There should be 2-3 days without treatment with Cellmune between applications. If symptoms come back, you should use Cellmune twice a day, as previously indicated, and go see your doctor to review your treatment.
If you accidentally ingest some ointment
If you accidentally ingest the ointment, consult your doctor or pharmacist as soon as possible. Do not try to induce vomiting.
If you forget to use Cellmune
If you forget to apply the ointment at the scheduled time, do so as soon as you remember and then continue as before.
If you have any other questions about using this medicine, ask your doctor or pharmacist.
Like all medicines, Cellmune can cause side effects, although not everybody gets them.
Very common (may affect more than 1 in 10 people):
Usually, these symptoms are mild to moderate and generally disappear within a week of using tacrolimus.
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
In adults, infections at the application site have been reported after treatment twice a week.
Post-marketing experience has also reported rosacea (facial redness), rosacea-like dermatitis, lentigo (presence of flat brown spots on the skin), edema at the application site, and herpes infections in the eyes.
Since its marketing, a very small number of people who have used tacrolimus ointment have had malignant diseases (e.g., lymphoma, including skin lymphoma and other skin tumors). However, it has not been confirmed or ruled out, according to the available evidence, whether there is a relationship with tacrolimus ointment treatment.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use Cellmune after the expiry date which is stated on the tube and carton, after EXP. The expiry date is the last day of the month stated.
Do not store above 25°C.
Discard opened tubes after 90 days from first opening, even if not empty. They should not be stored for future use.
Medicines should not be disposed of via wastewater or household waste. Return the containers and any unused medicine to a pharmacy for disposal. If you are unsure, ask your pharmacist how to dispose of the containers and any unused medicine. This will help protect the environment.
One gram of Cellmune contains 1 mg of tacrolimus (as tacrolimus monohydrate).
Appearance and packaging
Cellmune is a white to slightly yellowish ointment.
It is available in tubes containing 10, 30, or 60 grams of ointment.
Not all pack sizes may be marketed.
Marketing Authorization Holder
Industrial Farmacéutica Cantabria, S.A.
Barrio Solía 30
La Concha de Villaescusa
39690 Cantabria (Spain)
Manufacturer
Laboratori Fundació Dau
Pol. Ind. Consorci Zone Franca, c/C, 12-14
08040 Barcelona (Spain)
This medicine is authorized in the Member States of the European Economic Area under the following names:
Spain: Cellmune 1 mg/g ointment
Portugal: Tacrolímus Cantabria 1 mg/g ointment
Italy: Carelimus 0.1% ointment
Date of last revision of this leaflet:March 2024
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)
The average price of CELLMUNE 1 mg/g OINTMENT in January, 2026 is around 23.37 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for CELLMUNE 1 mg/g OINTMENT – subject to medical assessment and local rules.